 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Celgene Corporation (CELG) discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe.
Its commercial stage products include REVLIMID, an immunomodulatory drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum.
The companys commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The companys pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor.
It has strategic collaborations with bluebird bio, Inc. to discover, develop, and commercialize gene therapies in oncology; FORMA Therapeutics Holdings to discover, develop, and commercialize drug candidates to regulate protein homeostasis; and Concert Pharmaceuticals, Inc. to develop deuterium-modified compounds for cancer and inflammation, as well as a strategic alliance with MorphoSys AG to advance CD38 Cancer Program MOR202 for Multiple Myeloma.
Shares have formed a bullish "flag" and higher share prices are expected to head higher from this formation.
52-Week Trading Range: $63.89 - $138.67
Entry Point: $138.10
Stop Loss: $131.10
Target Price: $151.80
CELG is leaving the postfolio after failing to gain 10% profit in 30 days. The company still remains a favorite as CELG should be heading higher.
